skip to Main Content

Expert Hopes Novel Approaches Improve Outlook in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Patients with pancreatic cancer are a difficult-to-treat population, as surgery continues to be the sole curative option.

However, ongoing clinical trials are investigating combination treatments with standard chemotherapies to improve outcomes.

For example, the standard frontline regimen nab-paclitaxel (Abraxane) plus gemcitabine is being studied in combination with the monoclonal antibody vantictumab (OMP-18R5) in a phase Ib dose-escalation study for patients with previously untreated stage IV pancreatic cancer (NCT02005315). Safety and maximum-tolerated dose are the study’s primary outcome measures. Read more . . .

Back To Top